BC Week In Review | Feb 9, 2018
Clinical News

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

In December, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) reported top-line data from 10 evaluable patients with platinum-sensitive or -resistant ovarian cancer in the first dose cohort of a Phase Ib trial showing that subcutaneous DPX-Survivac plus twice-daily...
BC Week In Review | Feb 9, 2017
Company News

Immunovaccine, Merck deal

Immunovaccine and Merck partnered to evaluate Immunovaccine’s DPX-Survivac in combination with Merck’s cancer drug Keytruda pembrolizumab plus low-dose cyclophosphamide in an open-label Phase II trial to treat advanced epithelial ovarian, fallopian tube or primary peritoneal...
BC Week In Review | Sep 5, 2016
Clinical News

DPX-Survivac: Additional Phase I/II data

Additional data from the open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial in 54 evaluable patients with stage IIc-IV ovarian cancer showed that subcutaneous DPX-Survivac in combination with low-dose cyclophosphamide led...
BC Week In Review | Aug 3, 2015
Company News

Immunovaccine, Incyte deal

The companies partnered non-exclusively to evaluate Immunovaccine’s DPX-Survivac in combination with epacadostat from Incyte plus low-dose oral cyclophosphamide in an open-label Phase Ib trial to treat platinum-sensitive ovarian cancer in about 20 patients who are...
BC Week In Review | Mar 30, 2015
Clinical News

DPX-Survivac: Phase II started

Immunovaccine began an open-label, North American Phase II trial to evaluate subcutaneous DPX-Survivac plus oral cyclophosphamide in up to 24 patients. Subjects will receive 2 doses of DPX-Survivac given 3 weeks apart followed by booster...
BC Week In Review | May 26, 2014
Clinical News

DPX-Survivac: Additional Phase I data

Data from 30 patients with stage IIc-IV advanced or recurrent ovarian cancer in the open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial showed that subcutaneous DPX-Survivac in combination with low-dose oral...
BioCentury | May 26, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) was up €0.29 to €11.32 on Friday after EMA's CHMP reiterated its recommendation against conditional approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic...
BC Week In Review | Jan 14, 2013
Clinical News

DPX-Survivac: Phase I/II data

Data from 18 ovarian cancer patients previously treated by surgery and chemotherapy in the open-label, dose-ranging Phase I portion of a North American Phase I/II trial showed that all 12 patients receiving subcutaneous DPX-Survivac in...
BC Week In Review | Oct 15, 2012
Clinical News

DPX-Survivac: Additional Phase I/II data

Interim data from 9 patients in the Phase I portion of a North American Phase I/II trial showed that 0.5 mL subcutaneous DPX-Survivac in combination with low-dose oral cyclophosphamide every 3 weeks for 6 weeks...
BC Week In Review | Jul 2, 2012
Clinical News

DPX-Survivac: Phase I/II data

Data from the first cohort (n=3) of the Phase I portion of a Phase I/II trial showed that 0.5 mL subcutaneous DPX-Survivac every 3 weeks for 6 weeks was well tolerated with no serious adverse...
Items per page:
1 - 10 of 11